Hospital Pharmacy Europe

Hospitalpharmacyeurope.com is a complimentary platform that supports the Hospital Pharmacy Europe (HPE) journal. Users can easily access the complete content of each issue online, allowing pharmacists to quickly find and read well-written articles on subjects that matter to them with just a click.

International, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1581927

India

#173803

Health/Pharmacy

#190

Traffic sources

Monthly visitors

Articles

Upgrade digital systems in hospital pharmacy, RPS says as Government spending review boosts NHS

2 weeks ago | hospitalpharmacyeurope.com | Helena Beer

The Royal Pharmaceutical Society is calling on the Government to commit to upgrading digital systems in hospital pharmacy as the chancellor Rachel Reeves announces her much-anticipated spending review. The NHS will receive a £29bn real terms funding boost over the next three years, Ms Reeves said. This equates to a 3% increase in annual day-to-day spending from 2023/24 to 2028/29, making the spending £226bn by the end of the period.
Colorectal cancer red flags often mistaken for medication side effects

2 weeks ago | hospitalpharmacyeurope.com | Helena Beer

Individuals with chronic conditions are more inclined to attribute bowel habit changes to medication side effects rather than suspecting colorectal cancer despite it being a red flag, a new study has found. Although screening practices and early diagnosis have improved, many colorectal cancer cases are diagnosed at an advanced stage, highlighting that symptoms can be challenging to recognise.
Discover the latest about IV medicines safety at our new HPE Virtual Study Day

3 weeks ago | hospitalpharmacyeurope.com | Helena Beer

Hospital Pharmacy Europe is delighted to launch its new series of free-to-attend Virtual Study Days, starting with a focus on intravenous (IV) medicines safety on 25 June 2025. Around 12,000 deaths occur in the UK annually as a result of IV medication errors and complications.
OPAT more cost-effective than inpatient care, study finds

3 weeks ago | hospitalpharmacyeurope.com | Helena Beer

Outpatient parenteral antimicrobial therapy (OPAT) can reduce treatment costs by an average of 36% compared to inpatient therapy, according to a first-of-its-kind study. The recently published systematic review and meta-analysis by international researchers considered 20 studies involving 2,790 patients. The average cost of OPAT per treatment episode was $10,454 compared to $16,492 for inpatient care.
Professor Shereen Nabhani-Gebara on upskilling and supporting the oncology pharmacy workforce

3 weeks ago | hospitalpharmacyeurope.com | Helena Beer

Despite the UK’s highly skilled oncology pharmacy workforce, staff shortages mean the sector is having to look at different ways of working to meet increasing demand on cancer services.
Bridging the access gap for biosimilars in severe asthma

1 month ago | hospitalpharmacyeurope.com | Helena Beer

Severe asthma affects a minority of patients but drives a disproportionate share of healthcare costs for this condition. Although biologics have improved outcomes for allergic phenotypes, their high price limits equitable access. Emerging biosimilars offer similar efficacy at lower costs and promise broader availability. In his latest commentary, Dr João Gonçalves PhD examines key regulatory milestones, pivotal trials and strategies for integrating omalizumab biosimilars into clinical practice.
Disparities in medication error reporting highlight patient safety inequalities

1 month ago | hospitalpharmacyeurope.com | Helena Beer

Patients’ gender, age and ethnicity significantly influence the likelihood of having a medication-related error formally reported, according to a cross-sectional study by Barts Health NHS Trust in London, UK. The findings of this first report assessing possible disparities in medicine-related incident reporting in England highlight that systematic support is required to reduce the variation of medicine error reporting among patients with key protected characteristics.
AMS programme improves optimal antibiotic use for pneumonia in children

1 month ago | hospitalpharmacyeurope.com | Helena Beer

A simple, multifaceted antibiotic stewardship programme significantly improves adherence to guidelines for treating non-severe community-acquired pneumonia in children, a quasi-experimental before and after study conducted at Nantes University Hospital has demonstrated. Electronic health record screening using predefined keywords identified 519 children between birth and 15 years and three months of age for inclusion in the study.
Dupilumab found to improve quality of life and reduce treatment-related anxiety in children

1 month ago | hospitalpharmacyeurope.com | Helena Beer

The ways in which children and adolescents with severe asthma and/or moderate-to-severe atopic dermatitis perceive their medication and quality of life has been assessed in a real-world exploratory study, with particular focus on dupilumab. The study included 57 paediatric patients (severe asthma: n = 31; moderate-to-severe atopic dermatitis: n = 21; both: n = 5) with a median age of 11 years and each received one structured interview with a trained pharmacist.
Translating infectious diseases knowledge into action: ESCMID Global 2025

1 month ago | hospitalpharmacyeurope.com | Helena Beer

The Congress of the European Society of Clinical Microbiology and Infectious Diseases – known as ESCMID Global – brings together leading experts in infectious diseases and clinical microbiology to exchange ideas and explore the latest innovations and cutting-edge research. Here, Gerry Hughes reports on some of the key themes and highlights from the recent 2025 gathering. The escalating global threat of antimicrobial resistance (AMR) demands evidence-informed, multidisciplinary action.